Exhibit 99.1
Applied Molecular Transport Reports Second Quarter 2022 Financial Results and
Provides Corporate Update
Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis
|
|
• |
Orphan indication with no FDA-approved products |
|
|
• |
Company granted end of Phase 2 meeting with FDA to discuss advancing into Phase 3 development |
Announced top-line data for AMT-101 MARKET Phase 2 combination trial in patients with moderate-to-severe ulcerative colitis (UC)
|
|
• |
Post hoc analysis suggests combination treatment earlier in the course of disease may be beneficial |
|
|
• |
Further analysis of patients with shorter duration of UC ongoing |
Anticipate Phase 2 top-line readout for oral AMT-101 in UC monotherapy in H2 2022, consistent with previous guidance
SOUTH SAN FRANCISCO, Calif., August 4, 2022 -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.
“We were pleased to recently announce that the company has been granted an end of Phase 2 meeting with FDA, based on the positive top-line data from our FILLMORE monotherapy trial in patients with chronic pouchitis,” said Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT. “The company remains focused on Phase 3 preparation for this important indication, and also looks forward to our remaining two top-line readouts for oral AMT-101 later this year and in 2023.”
Recent Business Highlights and Anticipated Milestones
|
|
• |
Announced positive Phase 2 top-line data in the AMT-101 FILLMORE monotherapy trial for patients with chronic pouchitis, an orphan indication with no FDA-approved products |
|
|
o |
Company granted end of Phase 2 meeting with FDA to discuss advancing to Phase 3 |
|
|
o |
AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated through the 12-week treatment period, in the most difficult-to-treat IBD patients where rapid, symptomatic improvement is critical |
|
|
o |
Met pre-specified efficacy endpoints, and achieved meaningful responses in stool frequency and histologic healing in both the 3mg and 10mg dosage groups |
|
|
o |
Independent DMC recommended advancing to Phase 3 with the 3 mg dose in chronic pouchitis |
|
|
• |
Announced Phase 2 top-line data in the AMT-101 MARKET combination trial with anti-TNFα in biologic-naïve patients with moderate-to-severe UC |
|
|
o |
Post hoc analysis suggests combination treatment earlier in the course of disease may be beneficial |
|
|
o |
Further analysis of patients with shorter duration of UC < 5 years ongoing |
|
|
o |
AMT-101 appeared safe and well-tolerated through the 8-week treatment period |
|
|
• |
Two ongoing Phase 2 trials for AMT-101, a GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule: |
|
|
o |
LOMBARD monotherapy trial for biologic-naïve and experienced patients with moderate-to-severe UC; Top-line data readout anticipated in H2 2022 |
|
|
o |
CASTRO combination trial with anti-TNFα for patients with RA who are partial or non-responders to anti-TNFα therapy; Top-line data readout anticipated in 2023 |
|
|
• |
Aligned senior management to support the recently announced strategic plan and late-stage focus of the company |
|
|
o |
Shawn Cross named president and chief operating officer |
|
|
o |
Brandon Hants assumed role of chief financial officer |
Financial Results for the Second Quarter Ended June 30, 2022
Research and development (R&D) expenses. Total R&D expenses for the second quarter of 2022 were $25.9 million, compared to $16.5 million for the same period in 2021. The overall increase was primarily related to higher expenses associated with clinical trials, increased headcount, facilities-related expenses and materials. Total R&D expenses for the second quarter of 2022 included nonrecurring charges related to the changes in its strategic plan of $3.1 million announced May 18, 2022.
General and administrative (G&A) expenses. Total G&A expenses for the second quarter of 2022 were $10.1 million, compared to $7.1 million for the same period in 2021. The overall increase was primarily due to increased headcount, professional fees and facilities-related expenses. Total G&A expenses for the second quarter of 2022 included nonrecurring charges related to the strategic plan of $0.7 million.
Net loss. Net loss for the second quarter of 2022 was $35.9 million, compared to $23.6 million for the same period in 2021. Stock-based compensation and depreciation and amortization for the second quarter of 2022 was $6.5 million, compared to $5.1 million for the same period in 2021.
Cash, cash equivalents, and investments. As of June 30, 2022, cash and cash equivalents were $95.8 million. The Company believes its cash and cash equivalents will be sufficient to allow the Company to fund its current operating plan for at least the next twelve months.
About AMT-101
AMT-101 is a novel GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, currently in development in Phase 2 clinical trials for chronic pouchitis, UC and RA. AMT-101 is designed to cross the intestinal epithelial (IE) barrier with limited entry into the bloodstream, thereby focusing IL-10 at the primary site of inflammation in IBD, along the intestinal tissue lamina propria, potentially avoiding the side effects observed with systemic administration.
About Applied Molecular Transport Inc.
AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates, by leveraging its technology platform to design and advance a multi-product pipeline to treat autoimmune, inflammatory, metabolic and other diseases. AMT is developing its oral biologic product candidates in patient-friendly oral dosage forms that are designed to either target local intestinal tissue or enter systemic circulation to precisely address the relevant pathophysiology of disease. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier.
AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements including statements relating to AMT’s plans, expectations, forecasts and future events. Such forward-looking statements include, but are not limited to, the potential of, and expectations regarding AMT’s technology platform and the extent to which it may enable the development of new products and AMT’s internal manufacturing capabilities, statements regarding scaling our organization, growth of clinical activities, or pipeline expansion, statements regarding the optimization or expansion of our product development plans or the design of future clinical trials, statements regarding the potential of AMT-101, AMT-126, AMT’s respiratory carrier technology or regarding AMT-101 and AMT-126 clinical trials, including the timing of data readouts from such trials, advancing product candidates to future phases of development, and program updates, milestones for such trials, and our ability to replicate past clinical development strategies, statements regarding the potential for AMT’s product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and assumptions regarding the biological mode of action of our product candidates and the potential to avoid side effects with our product candidates. In some cases, you can identify forward-looking statements by terminology such as “believe,” “estimate,” “intend,” “may,” “plan,” “potentially,” “will,” “expect,” “enable,” “likely” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual events, trends or results could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements based on various factors. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in AMT’s Annual and Quarterly Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission (the “SEC”), and AMT’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and AMT assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Applied Molecular Transport Inc.
(unaudited)
(in thousands, except share and per share amounts)
|
|
|
June 30, |
|
|
December 31, |
|
||
|
|
|
2022 |
|
|
2021 |
|
||
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
95,830 |
|
|
$ |
159,821 |
|
|
Prepaid expenses |
|
|
4,347 |
|
|
|
6,685 |
|
|
Other current assets |
|
|
1,131 |
|
|
|
594 |
|
|
Total current assets |
|
|
101,308 |
|
|
|
167,100 |
|
|
Property and equipment, net |
|
|
9,400 |
|
|
|
6,998 |
|
|
Operating lease right-of-use assets, net |
|
|
34,512 |
|
|
|
38,142 |
|
|
Finance lease right-of-use assets, net |
|
|
694 |
|
|
|
652 |
|
|
Restricted cash |
|
|
1,025 |
|
|
|
1,025 |
|
|
Other assets |
|
|
323 |
|
|
|
121 |
|
|
Total assets |
|
$ |
147,262 |
|
|
$ |
214,038 |
|
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,313 |
|
|
$ |
2,211 |
|
|
Accrued expenses |
|
|
9,616 |
|
|
|
8,226 |
|
|
Operating lease liabilities, current |
|
|
4,018 |
|
|
|
3,584 |
|
|
Finance lease liabilities, current |
|
|
262 |
|
|
|
237 |
|
|
Total current liabilities |
|
|
16,209 |
|
|
|
14,258 |
|
|
Operating lease liabilities |
|
|
32,932 |
|
|
|
35,785 |
|
|
Finance lease liabilities |
|
|
125 |
|
|
|
167 |
|
|
Other liabilities |
|
|
244 |
|
|
|
241 |
|
|
Total liabilities |
|
|
49,510 |
|
|
|
50,451 |
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
|
Common stock |
|
|
4 |
|
|
|
4 |
|
|
Additional paid-in capital |
|
|
415,913 |
|
|
|
403,228 |
|
|
Accumulated other comprehensive income |
|
|
— |
|
|
|
— |
|
|
Accumulated deficit |
|
|
(318,165 |
) |
|
|
(239,645 |
) |
|
Total stockholders’ equity |
|
|
97,752 |
|
|
|
163,587 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
147,262 |
|
|
$ |
214,038 |
|
Applied Molecular Transport Inc.
Condensed Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share and per share amounts)
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
|
June 30, |
|
|
June 30, |
|
||||||||||
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
25,909 |
|
|
$ |
16,534 |
|
|
$ |
57,148 |
|
|
$ |
31,415 |
|
|
General and administrative |
|
|
10,113 |
|
|
|
7,093 |
|
|
|
21,450 |
|
|
|
12,692 |
|
|
Total operating expenses |
|
|
36,022 |
|
|
|
23,627 |
|
|
|
78,598 |
|
|
|
44,107 |
|
|
Loss from operations |
|
|
(36,022 |
) |
|
|
(23,627 |
) |
|
|
(78,598 |
) |
|
|
(44,107 |
) |
|
Interest income, net |
|
|
75 |
|
|
|
59 |
|
|
|
72 |
|
|
|
99 |
|
|
Other income (expense), net |
|
|
2 |
|
|
|
(62 |
) |
|
|
6 |
|
|
|
(84 |
) |
|
Net loss |
|
$ |
(35,945 |
) |
|
$ |
(23,630 |
) |
|
$ |
(78,520 |
) |
|
$ |
(44,092 |
) |
|
Net loss per share, basic and diluted |
|
$ |
(0.93 |
) |
|
$ |
(0.62 |
) |
|
$ |
(2.03 |
) |
|
$ |
(1.20 |
) |
|
Weighted-average shares of common stock outstanding, basic and diluted |
|
|
38,748,741 |
|
|
|
38,128,095 |
|
|
|
38,695,350 |
|
|
|
36,680,973 |
|
|
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(35,945 |
) |
|
$ |
(23,630 |
) |
|
$ |
(78,520 |
) |
|
$ |
(44,092 |
) |
|
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized loss on investments |
|
|
— |
|
|
|
(19 |
) |
|
|
— |
|
|
|
(21 |
) |
|
Total comprehensive loss |
|
$ |
(35,945 |
) |
|
$ |
(23,649 |
) |
|
$ |
(78,520 |
) |
|
$ |
(44,113 |
) |
-----------------------------------
Refer to the Company’s applicable SEC filings for previously reported periods.
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com
Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com